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Abstract
Male sex determination in humans is controlled by the SRY gene, which encodes a transcriptional regulator containing a con-
served high mobility group box domain (HMG-box) required for DNA binding. Mutations in the SRY HMG-box affect protein 
function, causing sex reversal phenotypes. In the present study, we describe a 19-year-old female presenting 46,XY karyotype 
with hypogonadism and primary amenorrhea that led to the diagnosis of 46,XY complete gonadal dysgenesis. The novel p.E89K 
missense mutation in the SRY HMG-box was identified as a de novo mutation. Electrophoretic mobility shift assays showed 
that p.E89K almost completely abolished SRY DNA-binding activity, suggesting that it is the cause of SRY function impairment. 
In addition, we report the occurrence of the p.G95R mutation in a 46,XY female with complete gonadal dysgenesis. According 
to the three-dimensional structure of the human SRY HMG-box, the substitution of the conserved glutamic acid residue by the 
basic lysine at position 89 introduces an extra positive charge adjacent to and between the positively charged residues R86 
and K92, important for stabilizing the HMG-box helix 2 with DNA. Thus, we propose that an electrostatic repulsion caused by 
the proximity of these positive charges could destabilize the tip of helix 2, abrogating DNA interaction. 
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In humans, as in other mammals, sex determination is 
controlled by a dominant switch located on the Y-chromo-
some, the SRY gene, also referred to as the sex-determining 
region on the Y (1,2). The human single copy monoexonic 
SRY gene encodes a 204-amino acid protein that contains 
a conserved domain formed by 79 residues known as the 
high mobility group box (HMG-box), which is flanked by two 
nuclear localization signals (3). The HMG-box character-
izes the SRY as a transcription regulator with DNA-binding 
and bending abilities (4-6). Mutations within the SRY gene 
sequence cause male-to-female sex reversal in XY individu-
als as a result of failure of indifferent gonads to develop 
into testes, leading to complete XY gonadal dysgenesis 
(46,XY CGD) (7), included among the 46,XY disorders of 
sex development (8). Patients with 46,XY CGD present 
a normal female phenotype and streak gonads at birth, 
whereas they will present primary amenorrhea and failure 
to develop female secondary characteristics at puberty. 
The importance of SRY function has been indicated by 
a number of studies describing amino acid changes within 
this protein in patients with 46,XY CGD (9). To date, up to 
68 mutations have been identified within the open reading 
frame of the SRY gene (10). The majority of these mutations 
are located within the HMG-box, highlighting the critical role 
of this domain in DNA binding and transcriptional activa-
tion (11). Although mutations outside the SRY HMG-box 
domain are rare, they can also cause 46,XY CGD (12,13). 
Furthermore, a small subset of reports describe familial 
mutations (13,14), whereas the majority are de novo muta-
tions affecting only one individual in a family. In summary, 
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a large spectrum of phenotypic variation is observed among 
patients carrying different SRY gene mutations; therefore, phe-
notype and genotype correlations in patients with XY gonadal 
dysgenesis are not straightforward. 
In the present study, the novel p.E89K and p.G95R muta-
tions within the SRY HMG-box were identified in patients with 
46,XY CGD. The E89 residue is conserved among the SRY 
proteins and the p.E89K mutation significantly affects the pro-
tein DNA-binding activity in vitro. Interestingly, both mutations 
introduce an extra positive charge adjacent to and between 
the positively charged residues R86 and K92 important for 
stabilizing the HMG-box helix 2 and DNA complex. The role 
of the electrostatic repulsion caused by the proximity of those 
positive charges on DNA interaction is discussed.
Patients and Methods
Patients
Patient 1. A 19-year-old female was referred to us due 
to hypogonadism and primary amenorrhea. She was born 
at term by normal delivery, but her birth weight is unknown. 
She was the first child of non-consanguineous parents in 
a sibship of 8 (6 sisters and 1 brother) with unremarkable 
family history. Upon physical examination, her weight 
was 42.4 kg and height 158 cm. She had female external 
genitalia with pubertal development in Tanner stage M1P2, 
and there was no dysmorphic picture. Cytogenetic analysis 
revealed a 46,XY karyotype. There were high levels of FSH 
(164 mIU/mL; normal range (NR): 1.5-12.4 mIU/mL) and 
LH (31.1 mIU/mL; NR: 1.7-8.6 mIU/mL), and ultrasonogra-
phy revealed infantile uterus, but no female gonads were 
visualized. Both dysgenetic gonads were removed and a 
microscopic gonadoblastoma (2 x 2 mm) was found in the 
right gonad. 
Patient 2. A 17-year-old female was referred to us 
due to hypogonadism and primary amenorrhea. She 
was born at term by normal delivery to nonconsanguine-
ous parents, with 2.6 kg and 46 cm of birth weight and 
length, respectively. Her mother had a stillborn girl and a 
first-trimester miscarriage, followed by an 18-year-old girl 
and the proposita; family history was unremarkable. On 
physical examination, her weight was 67.8 kg and height 
174.3 cm. She had female external genitalia with pubertal 
development in Tanner stage M1P3, and no dysmorphic 
characteristics. Cytogenetic analysis revealed a 46,XY 
karyotype. There were high levels of FSH (80.1 mIU/mL; 
NR: 1.5-12.4 mIU/mL) and LH (21.4 mIU/mL; NR: 1.7-8.6 
mIU/mL), and ultrasonography revealed infantile uterus, 
but no female gonads were visualized. The patient was 
informed about the risk of malignant development of go-
nadal tissue and was referred to other services in order 
to perform prophylactic bilateral gonadectomy. 
The study was approved by the Ethics Committee of the 
Universidade Estadual de Campinas, and informed consent 
was obtained from the patients and controls.
Methods
Genomic DNA was extracted from peripheral blood by 
standard techniques (15). PCR was performed with 0.5 
µg genomic DNA, 10% DMSO, 200 µM each deoxyribo-
nucleoside triphosphates, 0.5 µM each primer, 1X Taq DNA 
polymerase buffer solution (Amersham-GE, USA), and 1.5 
U Taq DNA polymerase (Invitrogen, USA). Each PCR con-
tained normal female and male control DNA. The SRY open 
reading frame was amplified as described before (13) and 
sequenced twice with products from different PCR assays. 
Both sense and antisense primers were used to confirm 
sequence results. Amplified SRY fragments were purified 
with Wizard SV Gel and PCR Clean-UP System (Promega, 
USA) and directly sequenced with the Big Dye Terminator 
Cycle Sequencing Kit V3.1 Ready Reaction (Applied Bio-
systems, USA). Wild-type and mutant SRY gene samples 
were amplified by PCR to be cloned into pET28A bacterial 
expression vector (Novagen, USA) to produce N-terminal 
His-tagged fusion proteins as described elsewhere (13). 
Resulting constructs were used to transform BL21 (DE3) 
competent Escherichia coli cells, and the expression of 
wild-type and mutant SRY proteins was induced with 0.1 
mM isopropyl-1-thio-beta-D-galactopyranoside (IPTG). 
Cells were collected and lysed and protein was purified 
with an Ni-NTA agarose column (Qiagen, Germany). 
SRY proteins were eluted and stored at -70°C. Specific 
oligonucleotides containing the SRY-target DNA sequence 
were synthesized and subsequently annealed to generate 
a double-stranded probe (oligoA) as previously described 
(13,16). The ds-oligonucleotide was labeled with (α-32P) 
dCTP (Amersham-GE) using the standard Klenow fill-in 
reaction. The mixtures were incubated in the presence of 
increasing concentrations of either normal or mutant SRY 
proteins. Electrophoretic mobility shift assays (EMSAs) were 
carried out on non-denaturing 6% polyacrylamide gels and 
the shifted bands were visualized on Hiperfilm MP autora-
diographies (Amersham-GE).
Results
The 380-bp amplified fragment encoding the SRY con-
served domain was sequenced with 46,XY CGD in both 
female patients. A hemizygous transition of a guanine (GAG) 
to an adenine (AAG) in codon 89 was observed in patient 1 
(Figure 1A). This novel mutation causes the substitution of 
a glutamic acid by a lysine (p.E89K) within the HMG-box of 
the SRY gene. Sequencing the whole SRY coding region 
did not show any other nucleotide variation. The patient’s 
father and brother did not present the nucleotide change, 
suggesting that this mutation had occurred as a de novo 
event. The p.G95R mutation was identified in patient 2 as 
a result of the GGA>CGA nucleotide change (Figure 1B).
To investigate the effect of the p.E89K mutation on the 
SRY DNA-binding activity, EMSAs were performed with 
the purified wild-type and mutant proteins. The assay with 
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increasing protein concentrations showed that the mutant 
protein was unable to bind to the DNA probe even at high 
concentrations, as compared to the wild-type protein, in-
dicating that the mutation drastically decreased the SRY 
DNA-binding activity (Figure 1C).
Discussion
In the present study, we report a case of p.G95R sub-
stitution associated with sex reversal and describe a novel 
mutation (p.E89K) within the SRY HMG-box in patients with 
Figure 1. Partial electropherograms of SRY gene DNA sequences of normal control and patients with 46,XY complete gonadal 
dysgenesis are shown. A, Patient 1 showing the G>A substitution that leads to a change in the amino acid E89 to K, within the 
highly conserved DNA-binding motif (HMG-box) of the SRY protein. B, Patient 2 showing the G>C substitution that leads to a 
change in the amino acid G95 to R, within the highly conserved DNA-binding motif (HMG-box) of the SRY protein. C, Effect of the 
p.E89K mutation on the DNA-binding activity of the SRY protein. Electrophoretic mobility shift assays (EMSA) were performed us-
ing the purified wild-type and mutant SRY proteins. Lane 1 corresponds to the 32P-labeled free probe. Lanes 2, 4, 6, and 8 corre-
spond to reactions comprising the probe + wild-type SRY protein at increasing concentrations (0.5, 1, 2.5, and 5 µg, respectively). 
The arrow indicates the SRY-DNA complex. Lanes 3, 5, 7, and 9 correspond to reactions containing the probe + mutant SRYE89K 
protein at increasing concentrations (0.5, 1, 2.5, and 5 µg, respectively). 
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